IL193484A0 - Gsk-3 inhibitors for the treatment of osteoporosis - Google Patents

Gsk-3 inhibitors for the treatment of osteoporosis

Info

Publication number
IL193484A0
IL193484A0 IL193484A IL19348408A IL193484A0 IL 193484 A0 IL193484 A0 IL 193484A0 IL 193484 A IL193484 A IL 193484A IL 19348408 A IL19348408 A IL 19348408A IL 193484 A0 IL193484 A0 IL 193484A0
Authority
IL
Israel
Prior art keywords
gsk
osteoporosis
inhibitors
treatment
Prior art date
Application number
IL193484A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Berg Anna Lena
Bhat Ratan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38475142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL193484(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Berg Anna Lena, Bhat Ratan filed Critical Astrazeneca Ab
Publication of IL193484A0 publication Critical patent/IL193484A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL193484A 2006-03-08 2008-08-14 Gsk-3 inhibitors for the treatment of osteoporosis IL193484A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78025206P 2006-03-08 2006-03-08
PCT/SE2007/000216 WO2007102770A1 (en) 2006-03-08 2007-03-06 Gsk-3 inhibitors for the treatment of osteoporosis

Publications (1)

Publication Number Publication Date
IL193484A0 true IL193484A0 (en) 2009-08-03

Family

ID=38475142

Family Applications (1)

Application Number Title Priority Date Filing Date
IL193484A IL193484A0 (en) 2006-03-08 2008-08-14 Gsk-3 inhibitors for the treatment of osteoporosis

Country Status (16)

Country Link
US (1) US7576093B2 (https=)
EP (1) EP1993550A4 (https=)
JP (1) JP2009529041A (https=)
KR (1) KR20080114717A (https=)
CN (1) CN101394851A (https=)
AR (1) AR059754A1 (https=)
AU (1) AU2007222199A1 (https=)
BR (1) BRPI0708619A2 (https=)
CA (1) CA2644751A1 (https=)
IL (1) IL193484A0 (https=)
MX (1) MX2008011417A (https=)
NO (1) NO20084182L (https=)
TW (1) TW200800203A (https=)
UY (1) UY30192A1 (https=)
WO (1) WO2007102770A1 (https=)
ZA (1) ZA200807234B (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137330A1 (en) * 2007-03-08 2010-06-03 Ratan Bhat Use
CA2743134A1 (en) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
KR20120120307A (ko) * 2010-01-19 2012-11-01 아스트라제네카 아베 피라진 유도체
CA2798760A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as inhibitors of atr kinase
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2568984A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
NZ603477A (en) 2010-05-12 2014-09-26 Vertex Pharma Compounds useful as inhibitors of atr kinase
MX2013000103A (es) 2010-06-23 2013-06-13 Vertex Pharma Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
MX2013011450A (es) 2011-04-05 2014-02-03 Vertex Pharma Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
LT2714677T (lt) * 2011-05-23 2018-12-10 Merck Patent Gmbh Piridino ir pirazino dariniai
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
EP2723747A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
CN108685922A (zh) 2011-09-30 2018-10-23 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013049722A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN106496173A (zh) 2011-09-30 2017-03-15 沃泰克斯药物股份有限公司 用于制备可用作atr激酶抑制剂的化合物的方法
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2015502925A (ja) 2011-11-09 2015-01-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
US8846918B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN108478577A (zh) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
EP2909202A1 (en) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
PL2970890T3 (pl) 2013-03-14 2020-11-16 The Brigham And Women's Hospital, Inc. Kompozycje i sposoby ekspansji i hodowli nabłonkowych komórek macierzystych
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
PT3077397T (pt) 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
CN103804312B (zh) * 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
MX373102B (es) 2014-06-05 2020-04-17 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
EP3189134A1 (en) 2014-09-03 2017-07-12 The Brigham and Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
US11021687B2 (en) 2016-01-08 2021-06-01 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
EP3562827A1 (en) 2016-12-30 2019-11-06 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
KR20260049706A (ko) * 2023-07-14 2026-04-14 재즈 파마슈티컬스 테라퓨틱스, 인크. Atr 억제제를 포함하는 리포좀 조성물의 사용 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010111298A (ko) 2000-02-05 2001-12-17 버텍스 파마슈티칼스 인코포레이티드 Ｅｒｋ의 억제제로서 유용한 피라졸 조성물
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
ES2316756T3 (es) * 2002-01-10 2009-04-16 F. Hoffmann-La Roche Ag Uso de un inhibidor de gsk-3beta en la fabricacion de un medicamento para incrementar la formacion osea.
WO2003076442A1 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Purine derivatives as kinase inhibitors
SE0203752D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
JP2007525953A (ja) * 2003-06-06 2007-09-13 ワイス 骨リモデリングを調節する物質を同定するための方法および材料、ならびにそれによって同定された物質
KR20060056377A (ko) * 2003-08-13 2006-05-24 카이론 코포레이션 Ｇｓｋ-3 억제제 및 그것의 사용
US20050064044A1 (en) * 2003-09-19 2005-03-24 Georges Rawadi GSK-3beta inhibitors in the treatment of bone-related diseases

Also Published As

Publication number Publication date
US20070213322A1 (en) 2007-09-13
WO2007102770A8 (en) 2008-01-31
TW200800203A (en) 2008-01-01
CN101394851A (zh) 2009-03-25
NO20084182L (no) 2008-12-05
BRPI0708619A2 (pt) 2011-06-07
CA2644751A1 (en) 2007-09-13
US7576093B2 (en) 2009-08-18
EP1993550A4 (en) 2010-04-21
AR059754A1 (es) 2008-04-30
WO2007102770A1 (en) 2007-09-13
UY30192A1 (es) 2007-10-31
MX2008011417A (es) 2008-09-22
JP2009529041A (ja) 2009-08-13
AU2007222199A1 (en) 2007-09-13
EP1993550A1 (en) 2008-11-26
KR20080114717A (ko) 2008-12-31
ZA200807234B (en) 2009-09-30

Similar Documents

Publication Publication Date Title
ZA200807234B (en) GSK-3 inhibitors for the treatment of osteoporosis
SI2383271T1 (sl) Aminokinoloni kot inhibitorji gsk-3
IL189048A0 (en) Gsk-3 inhibitors
ZA200608221B (en) Thiadlazolidinones as GSK-3 Inhibitors
AP2870A (en) Odcase inhibitors for the treatment of malaria
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
IL185485A0 (en) Use of pde7 inhibitors for the treatment of neuropathic pain
SI2054088T1 (sl) Naprava za obdelavo vsebnikov
GB0823480D0 (en) Devices for the treatment of fluids
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
EP2352501A4 (en) COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
ZA200707147B (en) Use of PDE7 inhibitors for the treatment of neuropathic pain
EP2023894A4 (en) FIXED COMBINATION DOSAGE FOR TREATING MIGRAINE
IL201466A0 (en) Use of hdac inhibitors for the treatment of bone destruction
HK1123977A (en) Gsk-3 inhibitors for the treatment of osteoporosis
GB0604782D0 (en) Use of substituted pyrimidinyl-2-piperazine compounds for the treatment of food related disorders
ZA201004090B (en) Methods for the inhibition of scarring
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
GB0602857D0 (en) The treatment of sialorrhoea
GB0602858D0 (en) The treatment of sialorrhoea
GB0602855D0 (en) The Treatment Of Sialorrhoea
ZA200800245B (en) JNK inhibitors for the treatment of endometriosis
PL1886669T3 (pl) Preparat o działaniu immunotropowym na bazie fosfoglukanu do leczenia przerostu migdałka gardłowego
GB0621474D0 (en) Composition for the treatment of halitosis